Literature DB >> 24735362

Subfractions and subpopulations of HDL: an update.

M Rizzo, J Otvos, D Nikolic, G Montalto, P P Toth, M Banach1.   

Abstract

High-density lipoproteins (HDL) are classified as atheroprotective because they are involved in transport of cholesterol to the liver, known as "reverse cholesterol transport (RCT)" exerting antioxidant and anti-inflammatory activities. There is also evidence for cytoprotective, vasodilatory, antithrombotic, and anti-infectious activities for these lipoproteins. HDLs are known by structural, metabolic and biologic heterogeneity. Thus, different methods are able to distinguish several subclasses of HDL. Different separation techniques appear to support different HDL fractions as being atheroprotective or related with lower cardiovascular (CV) risk. However, HDL particles are not always protective. Modification of constituents of HDL particles (primarily in proteins and lipids) can lead to the decrease in their activity and induce proatherogenic properties, especially when isolated from patients with augmented systemic inflammation. According to available studies, it seems that HDL functionality may be a better therapeutic target than HDL cholesterol quantity; however, it is still disputable which subfractions are most beneficial. There is mounting evidence supporting HDL subclasses as an important biomarker to predict and/or reduce CV risk. In this review we discuss recent notices on atheroprotective and functional characteristic of different HDL subfractions. Also, we provide a brief overview of the different methods used by clinicians and researchers to separate HDL subfractions. Ongoing and future investigations will yield important new information if any given separation method might represent a 'gold standard', and which subfractions are reliable markers of CV risk and/or potential targets of novel, more focused, and effective therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24735362     DOI: 10.2174/0929867321666140414103455

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  31 in total

1.  Refocusing the AIM on HDL in the metabolic syndrome.

Authors:  Robert W McGarrah
Journal:  Atherosclerosis       Date:  2016-07-02       Impact factor: 5.162

2.  Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.

Authors:  James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden
Journal:  J Clin Lipidol       Date:  2018-01-12       Impact factor: 4.766

3.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative.

Authors:  Seth S Martin; Arif A Khokhar; Heidi T May; Krishnaji R Kulkarni; Michael J Blaha; Parag H Joshi; Peter P Toth; Joseph B Muhlestein; Jeffrey L Anderson; Stacey Knight; Yan Li; John A Spertus; Steven R Jones
Journal:  Eur Heart J       Date:  2014-06-30       Impact factor: 29.983

4.  In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters.

Authors:  Demidmaa Tuvdendorj; Alejandro O Munoz; Viviana Ruiz-Barros; Jean-Marc Schwarz; Giuseppe Montalto; Manisha Chandalia; Lawrence C Sowers; Manfredi Rizzo; Elizabeth J Murphy; Nicola Abate
Journal:  Atherosclerosis       Date:  2016-06-13       Impact factor: 5.162

5.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

6.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

7.  High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.

Authors:  Robert W McGarrah; Damian M Craig; Carol Haynes; Z Elaine Dowdy; Svati H Shah; William E Kraus
Journal:  Atherosclerosis       Date:  2016-01-11       Impact factor: 5.162

8.  Single-Particle Tracking of Human Lipoproteins.

Authors:  Michel de Messieres; Abby Ng; Cornelio J Duarte; Alan T Remaley; Jennifer C Lee
Journal:  Anal Chem       Date:  2015-12-14       Impact factor: 6.986

Review 9.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

10.  Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies.

Authors:  Trine L Wilkens; Kaare Tranæs; Jane N Eriksen; Lars O Dragsted
Journal:  Nutr Rev       Date:  2022-04-08       Impact factor: 6.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.